Allergan, Inc.

University of Michigan

Other

Ester Fernandez-Salas

Kei Roger Aoki

Lance Steward

Marcella A Gilmore

Joseph Francis

Shengwen Li

Sanjiv Ghanshani

Joanne Wang

Patton E Garay

K Roger Aoki

Todd M Herrington

Hong Zhu

J Oliver Dolly

Lina Wong

D Dianne Hodges

Wei-Jen Lin

Athena Spanoyannis

Dianne D Hodges

Lance E Steward

Shaomeng Wang

Donna McEachern

Birgitte P S Jacky

Longchuan Bai

Marc F Verhagen

Dudley J Williams

Fuming Xu

D Diane Hodges

Ron S Broide

Patrick Michael Hughes

Terrence J Hunt

Chao-Yie Yang

Jeanne Stuckey

Bing Zhou

Jianfeng Lu

Yang Hu

Jiantao Hu

David C Rupp

Kenton B Abel

Eric A Forssen

Chong Qin

Rohan Rej

Weiguo Xiang

Swati Gupta

Zhuo Chen

Anuradha Dixit

Gary Shimizu

Birgitte Ps Jacky

Ronald G Miller

Kei Rogers Aoki

Mi Wang

Changwei Wang

Brian Cai

Catherine Rheaume

Lina S Wong

Zhou Chen

Kei Roger Acki

Joseph A Francis

Patton E Gary

Lanoe E Steward

The present disclosure provides compounds represented by Formula I: wherein R, R, R, and Rare as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

Imidazopyrimidines as EED inhibitors and the use thereof

The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, R, R, R, R, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer. 

Fused 1,4-oxazepines as BET protein degraders

The present specification discloses SNAP-25 compositions, methods of making &#x3b1;-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the Presidue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, &#x3b1;-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the Presidue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing &#x3b1;-BoNT/A antibodies.

Immuno-based botulinum toxin serotype A activity assays

The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, R, Y, &#x2550;, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer. 

BET bromodomain protein degraders with cleavable linkers

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

Immuno-based retargeted endopeptidase activity assays

Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.

Method of detecting cleaved SNAP25 in tissue samples

The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.

Degradable clostridial toxins

The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.

Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A

Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.

Formulations of biologics for intravesical instillation

Degradable Clostridial toxins

Growing community of inventors

Fullerton, CA, United States of America

Ester Fernandez-Salas